EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nurix Therapeutics's enterprise value is $614.46 Mil.
Nurix Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 was $-142.97 Mil. Therefore, Nurix Therapeutics's EV-to-EBITDA for today is -4.30.
The historical rank and industry rank for Nurix Therapeutics's EV-to-EBITDA or its related term are showing as below:
NRIX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.02 Med: -2.84 Max: 0.08
Current: -4.3
During the past 6 years, the highest EV-to-EBITDA of Nurix Therapeutics was 0.08. The lowest was -24.02. And the median was -2.84.
NRIX's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs NRIX: -4.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Nurix Therapeutics's stock price is $13.58.
Nurix Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was $-2.660. Therefore, Nurix Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nurix Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Nurix Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Nurix Therapeutics Annual Data
Trend
Nov18
Nov19
Nov20
Nov21
Nov22
Nov23
EV-to-EBITDA
-
-21.90
-8.98
-1.66
-0.32
Nurix Therapeutics Quarterly Data
May19
Aug19
Nov19
Feb20
May20
Aug20
Nov20
Feb21
May21
Aug21
Nov21
Feb22
May22
Aug22
Nov22
Feb23
May23
Aug23
Nov23
Feb24
EV-to-EBITDA
-1.05
-1.38
-1.11
-0.32
-2.74
Competitive Comparison
For the Biotechnology subindustry, Nurix Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's EV-to-EBITDA falls into.
Nurix Therapeutics EV-to-EBITDA Calculation
Nurix Therapeutics's EV-to-EBITDA for today is calculated as:
Nurix Therapeutics's current Enterprise Value is $614.46 Mil.
Nurix Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-142.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nurix Therapeutics's PE Ratio for today is calculated as:
Nurix Therapeutics's share price for today is $13.58.
Nurix Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nurix Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nurix Therapeutics (Nurix Therapeutics) Business Description
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your 